Matches in SemOpenAlex for { <https://semopenalex.org/work/W2992509938> ?p ?o ?g. }
- W2992509938 endingPage "704" @default.
- W2992509938 startingPage "693" @default.
- W2992509938 abstract "Rationale & ObjectiveOn account of the high prevalence of cardiovascular disease in patients with kidney failure, clinical practice guidelines recommend regular screening for asymptomatic coronary artery disease (CAD) in patients on the kidney transplant waitlist. To date, the cost-effectiveness of such screening has not been evaluated. A Canadian-Australasian randomized controlled trial of screening kidney transplant candidates for CAD (CARSK) is currently is being conducted to answer this question. We conducted a cost-utility analysis to determine, before completion of the trial, the cost-effectiveness of no further screening versus regular screening for asymptomatic CAD and to evaluate potential influential variables that may affect results of the economic evaluation.Study DesignA modeled cost-utility analysis.Setting & PopulationA theoretical cohort of adult Australian and New Zealand kidney transplant candidates on the waitlist.InterventionNo further screening for asymptomatic CAD versus regular protocolized screening (annual or second yearly) for CAD after kidney transplant waitlisting.OutcomesIncremental cost-effectiveness ratio, reported as cost per quality-adjusted life-year (QALY).Model, Perspectives, & TimeframeMarkov microsimulation model, health system perspective and over a lifetime horizon.ResultsIn the base case, the incremental cost-effectiveness ratio of no further screening was $11,122 per QALY gained when compared with regular screening. No further screening increased survival by 0.49 life-year or 0.35 QALY. One-way sensitivity analyses identified the costs of transplantation in the first year and CAD prevalence as the most influential variables. Probabilistic sensitivity analyses showed that 94% of the simulations were cost-effective below a willingness-to-pay threshold of $50,000 per QALY gained.LimitationsRates of cardiovascular events in waitlisted candidates and transplant recipients are limited in the contemporary era. The results may not be generalizable to populations outside Australia and New Zealand.ConclusionsNo further screening for CAD after waitlisting is likely to be cost-effective and may improve survival. Precision around CAD prevalence estimates and health care resource use will reduce existing uncertainty. On account of the high prevalence of cardiovascular disease in patients with kidney failure, clinical practice guidelines recommend regular screening for asymptomatic coronary artery disease (CAD) in patients on the kidney transplant waitlist. To date, the cost-effectiveness of such screening has not been evaluated. A Canadian-Australasian randomized controlled trial of screening kidney transplant candidates for CAD (CARSK) is currently is being conducted to answer this question. We conducted a cost-utility analysis to determine, before completion of the trial, the cost-effectiveness of no further screening versus regular screening for asymptomatic CAD and to evaluate potential influential variables that may affect results of the economic evaluation. A modeled cost-utility analysis. A theoretical cohort of adult Australian and New Zealand kidney transplant candidates on the waitlist. No further screening for asymptomatic CAD versus regular protocolized screening (annual or second yearly) for CAD after kidney transplant waitlisting. Incremental cost-effectiveness ratio, reported as cost per quality-adjusted life-year (QALY). Markov microsimulation model, health system perspective and over a lifetime horizon. In the base case, the incremental cost-effectiveness ratio of no further screening was $11,122 per QALY gained when compared with regular screening. No further screening increased survival by 0.49 life-year or 0.35 QALY. One-way sensitivity analyses identified the costs of transplantation in the first year and CAD prevalence as the most influential variables. Probabilistic sensitivity analyses showed that 94% of the simulations were cost-effective below a willingness-to-pay threshold of $50,000 per QALY gained. Rates of cardiovascular events in waitlisted candidates and transplant recipients are limited in the contemporary era. The results may not be generalizable to populations outside Australia and New Zealand. No further screening for CAD after waitlisting is likely to be cost-effective and may improve survival. Precision around CAD prevalence estimates and health care resource use will reduce existing uncertainty." @default.
- W2992509938 created "2019-12-13" @default.
- W2992509938 creator A5003765303 @default.
- W2992509938 creator A5021944237 @default.
- W2992509938 creator A5033662895 @default.
- W2992509938 creator A5034982958 @default.
- W2992509938 creator A5039834479 @default.
- W2992509938 creator A5064952058 @default.
- W2992509938 creator A5073772726 @default.
- W2992509938 date "2020-05-01" @default.
- W2992509938 modified "2023-09-28" @default.
- W2992509938 title "Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis" @default.
- W2992509938 cites W1939259427 @default.
- W2992509938 cites W1970564831 @default.
- W2992509938 cites W1979236706 @default.
- W2992509938 cites W1996082994 @default.
- W2992509938 cites W2008162308 @default.
- W2992509938 cites W2017778372 @default.
- W2992509938 cites W2018155014 @default.
- W2992509938 cites W2024491306 @default.
- W2992509938 cites W2024754526 @default.
- W2992509938 cites W2026399893 @default.
- W2992509938 cites W2033053240 @default.
- W2992509938 cites W2039995580 @default.
- W2992509938 cites W2046214493 @default.
- W2992509938 cites W2050031203 @default.
- W2992509938 cites W2051896332 @default.
- W2992509938 cites W2058056848 @default.
- W2992509938 cites W2069263866 @default.
- W2992509938 cites W2071289468 @default.
- W2992509938 cites W2099285088 @default.
- W2992509938 cites W2109968192 @default.
- W2992509938 cites W2140780083 @default.
- W2992509938 cites W2143505273 @default.
- W2992509938 cites W2155801921 @default.
- W2992509938 cites W2163483559 @default.
- W2992509938 cites W2167254362 @default.
- W2992509938 cites W2613307563 @default.
- W2992509938 cites W2742835189 @default.
- W2992509938 cites W2945141025 @default.
- W2992509938 cites W3148238976 @default.
- W2992509938 doi "https://doi.org/10.1053/j.ajkd.2019.10.001" @default.
- W2992509938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31810731" @default.
- W2992509938 hasPublicationYear "2020" @default.
- W2992509938 type Work @default.
- W2992509938 sameAs 2992509938 @default.
- W2992509938 citedByCount "13" @default.
- W2992509938 countsByYear W29925099382020 @default.
- W2992509938 countsByYear W29925099382021 @default.
- W2992509938 countsByYear W29925099382022 @default.
- W2992509938 countsByYear W29925099382023 @default.
- W2992509938 crossrefType "journal-article" @default.
- W2992509938 hasAuthorship W2992509938A5003765303 @default.
- W2992509938 hasAuthorship W2992509938A5021944237 @default.
- W2992509938 hasAuthorship W2992509938A5033662895 @default.
- W2992509938 hasAuthorship W2992509938A5034982958 @default.
- W2992509938 hasAuthorship W2992509938A5039834479 @default.
- W2992509938 hasAuthorship W2992509938A5064952058 @default.
- W2992509938 hasAuthorship W2992509938A5073772726 @default.
- W2992509938 hasConcept C112930515 @default.
- W2992509938 hasConcept C126322002 @default.
- W2992509938 hasConcept C177713679 @default.
- W2992509938 hasConcept C184834754 @default.
- W2992509938 hasConcept C2777910003 @default.
- W2992509938 hasConcept C2778213512 @default.
- W2992509938 hasConcept C2778653478 @default.
- W2992509938 hasConcept C2780303639 @default.
- W2992509938 hasConcept C2911091166 @default.
- W2992509938 hasConcept C3019080777 @default.
- W2992509938 hasConcept C515549039 @default.
- W2992509938 hasConcept C64332521 @default.
- W2992509938 hasConcept C71924100 @default.
- W2992509938 hasConcept C72563966 @default.
- W2992509938 hasConceptScore W2992509938C112930515 @default.
- W2992509938 hasConceptScore W2992509938C126322002 @default.
- W2992509938 hasConceptScore W2992509938C177713679 @default.
- W2992509938 hasConceptScore W2992509938C184834754 @default.
- W2992509938 hasConceptScore W2992509938C2777910003 @default.
- W2992509938 hasConceptScore W2992509938C2778213512 @default.
- W2992509938 hasConceptScore W2992509938C2778653478 @default.
- W2992509938 hasConceptScore W2992509938C2780303639 @default.
- W2992509938 hasConceptScore W2992509938C2911091166 @default.
- W2992509938 hasConceptScore W2992509938C3019080777 @default.
- W2992509938 hasConceptScore W2992509938C515549039 @default.
- W2992509938 hasConceptScore W2992509938C64332521 @default.
- W2992509938 hasConceptScore W2992509938C71924100 @default.
- W2992509938 hasConceptScore W2992509938C72563966 @default.
- W2992509938 hasFunder F4320334705 @default.
- W2992509938 hasIssue "5" @default.
- W2992509938 hasLocation W29925099381 @default.
- W2992509938 hasLocation W29925099382 @default.
- W2992509938 hasOpenAccess W2992509938 @default.
- W2992509938 hasPrimaryLocation W29925099381 @default.
- W2992509938 hasRelatedWork W1971280286 @default.
- W2992509938 hasRelatedWork W2034847231 @default.
- W2992509938 hasRelatedWork W2041145027 @default.
- W2992509938 hasRelatedWork W2047049447 @default.
- W2992509938 hasRelatedWork W2068575303 @default.